AMG National Trust Bank Takes $256,000 Position in CME Group Inc. (NASDAQ:CME)

AMG National Trust Bank purchased a new stake in shares of CME Group Inc. (NASDAQ:CME - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 965 shares of the financial services provider's stock, valued at approximately $256,000.

Several other hedge funds and other institutional investors have also made changes to their positions in CME. Wayfinding Financial LLC acquired a new stake in shares of CME Group during the first quarter worth $25,000. Cornerstone Planning Group LLC increased its stake in CME Group by 122.2% during the first quarter. Cornerstone Planning Group LLC now owns 100 shares of the financial services provider's stock worth $26,000 after purchasing an additional 55 shares during the period. New Age Alpha Advisors LLC increased its stake in shares of CME Group by 50.0% during the fourth quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider's stock worth $30,000 after buying an additional 43 shares during the period. Golden State Wealth Management LLC increased its stake in CME Group by 612.5% in the first quarter. Golden State Wealth Management LLC now owns 114 shares of the financial services provider's stock valued at $30,000 after purchasing an additional 98 shares during the last quarter. Finally, Alpine Bank Wealth Management acquired a new stake in shares of CME Group in the first quarter valued at approximately $32,000. Hedge funds and other institutional investors own 87.75% of the company's stock.

CME Group Trading Up 0.1%

Shares of NASDAQ:CME traded up $0.17 during trading on Thursday, reaching $276.65. The company's stock had a trading volume of 737,717 shares, compared to its average volume of 2,374,738. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13. CME Group Inc. has a 12 month low of $193.25 and a 12 month high of $290.79. The stock has a market capitalization of $99.69 billion, a PE ratio of 27.87, a price-to-earnings-growth ratio of 4.79 and a beta of 0.44. The firm's 50 day simple moving average is $276.31 and its two-hundred day simple moving average is $261.54.

CME Group (NASDAQ:CME - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.91 by $0.05. CME Group had a net margin of 57.71% and a return on equity of 14.03%. The company had revenue of $1.69 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same period last year, the company posted $2.56 earnings per share. CME Group's revenue was up 10.4% compared to the same quarter last year. On average, research analysts predict that CME Group Inc. will post 10.49 EPS for the current fiscal year.

CME Group Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, June 25th. Investors of record on Monday, June 9th were given a dividend of $1.25 per share. The ex-dividend date of this dividend was Monday, June 9th. This represents a $5.00 dividend on an annualized basis and a yield of 1.81%. CME Group's payout ratio is presently 50.30%.

Insider Buying and Selling

In other CME Group news, Director Charles P. Carey sold 3,000 shares of the stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $272.56, for a total transaction of $817,680.00. Following the sale, the director directly owned 5,400 shares in the company, valued at $1,471,824. This represents a 35.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Daniel G. Kaye sold 500 shares of the firm's stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $282.42, for a total transaction of $141,210.00. Following the transaction, the director directly owned 3,668 shares in the company, valued at $1,035,916.56. The trade was a 12.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,400 shares of company stock worth $3,152,410 over the last ninety days. 0.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on CME shares. Barclays dropped their price target on CME Group from $299.00 to $298.00 and set an "equal weight" rating for the company in a research report on Thursday. Citigroup upped their price objective on CME Group from $265.00 to $275.00 and gave the stock a "neutral" rating in a research note on Thursday, July 3rd. Keefe, Bruyette & Woods boosted their target price on CME Group from $265.00 to $273.00 and gave the stock a "market perform" rating in a research report on Thursday, April 24th. UBS Group reiterated a "neutral" rating and set a $305.00 price target on shares of CME Group in a research note on Thursday. Finally, Morgan Stanley raised their price target on CME Group from $301.00 to $304.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Four equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, CME Group has a consensus rating of "Hold" and an average target price of $261.73.

CME Group Company Profile

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.